Cynata reports Phase I data for mesenchymal stem cell GvHD product

Cynata Therapeutics Ltd. (ASX:CYP) reported data from eight evaluable patients with steroid-resistant grade II-IV acute graft-versus-host disease (GvHD) in the first cohort of the Phase I CYP-GvHD-P1-01 trial showing that CYP-001 led an overall response rate (ORR) by day 100 of 100%, including four complete responses and four partial responses. No treatment-related serious adverse events were reported. One patient died after developing pneumonia that was not considered related to treatment.

The trial is enrolling patients with acute GvHD after receiving an allogeneic hematopoietic stem cell transplant (HSCT) for a hematological disorder. Patients in the first cohort received 1 million cells/kg IV CYP-001 on days 0 and 7. The second cohort of the trial is enrolling eight patients to receive 2 million cells/kg IV CYP-001 on days 0 and 7...